A Study of Interstitial Lung Disease Relating to the Development of Fibrosis in the Lungs

Overview

About this study

The purpose of this study is to investigate the possibility that B lymphocytes (a kind of white blood cell ) may be contributing to the development of fibrosis in the lungs. This study will examine if B lymphocytes, isolated from blood, can induce the stimulation of fibroblasts. Fibroblasts are cells that are responsible for the formation of scarring in the lungs. Specific markers found in the surface of B lymphocytes will also be investigated to see if it can be identified why these cells may induce the development of fibrosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients have to have radiological or pathological diagnosis of fibrotic ILD based on the current American thoracic society guidelines.

Exclusion Criteria:

No radiological or pathological data
No clear diagnosis of fibrosing ILD
Use of prednisone, or other immunosuppressive medication over the last 6 months (unless it is a sarcoidosis patient)
Had been on rituximab or other B cell depleted therapy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Eva Carmona Porquera, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Eva Carmona Porquera, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials